These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35583812)

  • 21. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
    Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
    J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 23. Update on pathogenesis and treatment of CLE.
    Privette ED; Werth VP
    Curr Opin Rheumatol; 2013 Sep; 25(5):584-90. PubMed ID: 23872903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cutaneous lupus erythematosus. Part 2: diagnostics and therapy].
    Kuhn A; Gensch K; Ständer S; Bonsmann G
    Hautarzt; 2006 Apr; 57(4):345-8; quiz 359. PubMed ID: 16547761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
    Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
    J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
    Kuhn A; Aberer E; Bata-Csörgő Z; Caproni M; Dreher A; Frances C; Gläser R; Klötgen HW; Landmann A; Marinovic B; Nyberg F; Olteanu R; Ranki A; Szepietowski JC; Volc-Platzer B
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):389-404. PubMed ID: 27859683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological characteristics of patients with cutaneous lupus erythematosus.
    Avilés Izquierdo JA; Cano Martínez N; Lázaro Ochaita P
    Actas Dermosifiliogr; 2014; 105(1):69-73. PubMed ID: 24268922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review.
    Chasset F; Francès C
    Drugs; 2019 Jul; 79(11):1199-1215. PubMed ID: 31228033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
    Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
    J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus.
    Zhu JL; Black SM; Chong BF
    Ann Transl Med; 2021 Mar; 9(5):429. PubMed ID: 33842650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioinformatics analyses of gene expression profile identify key genes and functional pathways involved in cutaneous lupus erythematosus.
    Gao ZY; Su LC; Wu QC; Sheng JE; Wang YL; Dai YF; Chen AP; He SS; Huang X; Yan GQ
    Clin Rheumatol; 2022 Feb; 41(2):437-452. PubMed ID: 34553293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus.
    Geraminejad P; Stone MS; Sontheimer RD
    Lupus; 2004; 13(6):473-7. PubMed ID: 15303576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus.
    Gammon B; Hansen C; Costner MI
    J Am Acad Dermatol; 2011 Oct; 65(4):717-721.e2. PubMed ID: 21641078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cutaneous lupus erythematosus: current approaches and future strategies.
    Shi H; Gudjonsson JE; Kahlenberg JM
    Curr Opin Rheumatol; 2020 May; 32(3):208-214. PubMed ID: 32141953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.